The device was returned and investigated.The returned analysis could not confirm the product quality problem¿irregular appearance during testing as no damage to the sgc hemostasis valve was found, nor could it confirm the reported difficult to advance-difficult dilator advancement, nor confirm difficult to remove-dilator.The discrepancy between what was reported (irregular appearance,) during preparation and what was observed (no damage to hemostasis valve) was likely due to the user's observation/interpretation of the rigidity of the hemostasis valve.The discrepancy between what was reported regarding difficult to advance- difficult dilator advancement and difficult to remove and what was observed (no difficulty/resistance advancing or removing) was likely due to the user's observation/interpretation of dilator advancement and retraction.A review of the lot history record revealed no manufacturing nonconformities issued to the reported lot that would have contributed to this complaint.Additionally, a review of the complaint history identified no other complaints reported for this lot.It should be noted as per mitraclip instructions for use (ifu) ntr/xtr system ce, states "warning: do not use excessive force to advance or manipulate the guide assembly".Hence, this is improper user technique as excessive force was applied per the account.However, it could not be confirmed whether the user error of applied excessive force led to, or contributed to, any damage to the device, as no damage was observed during return analysis.A cause for the reported product quality problem- irregular appearance, difficult to advance-difficult dilator advancement, and difficult to remove could not be determined.The reported improper or incorrect procedure was due to the force applied to advance the dilator which is deviation from the instructions for use.There is no indication of a product issue with respect to manufacture, design, or labeling.
|